Vora, Sadhna
Harvard University · Massachusetts General Hospital
3 papers on CoChat
Most cited papers
- Verified
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell
PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies
Cited by 438
- Verified
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine
PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies
Cited by 332
- Verified
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 106
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free